Episode Details

In this episode of The BioHub Podcast by Avetix, Ben sits down with Dr. Arun Swaminathan, CEO of Coya Therapeutics, a clinical-stage biotechnology company developing therapies designed to enhance regulatory T cell function and target systemic inflammation and neuroinflammation.

Arun brings more than 20 years of healthcare leadership experience across corporate strategy, business development, operations, and deal-making. At Coya, he is helping lead the company’s work in severe neurodegenerative diseases, including ALS, Alzheimer’s disease, frontotemporal dementia, and Parkinson’s disease, with a focus on immunomodulatory and Treg-based therapeutic approaches.

In this conversation, we discuss the evolving treatment landscape in neurodegeneration, the role of neuroinflammation in CNS drug development, what it takes to build and finance a clinical-stage biotech, and how combination therapeutic strategies could shape the next generation of disease-modifying treatments.